LEGAL PROCEEDINGS (Details Narrative) |
1 Months Ended | 12 Months Ended | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 08, 2025
USD ($)
|
Jul. 11, 2024
USD ($)
|
Jul. 11, 2024
ILS (₪)
|
Nov. 01, 2023
ILS (₪)
|
Oct. 26, 2023
USD ($)
|
Jan. 18, 2022
ILS (₪)
|
Mar. 31, 2018
USD ($)
|
Nov. 30, 2024
USD ($)
|
Dec. 31, 2024 |
Sep. 05, 2024
$ / shares
|
Jul. 14, 2024
$ / shares
|
May 22, 2024
$ / shares
|
Apr. 23, 2024
$ / shares
|
Apr. 18, 2024
$ / shares
|
Mar. 07, 2024
$ / shares
|
Jan. 29, 2024
shares
|
Nov. 01, 2023
USD ($)
$ / shares
shares
|
Nov. 01, 2023
ILS (₪)
shares
|
Sep. 06, 2023
USD ($)
|
Feb. 23, 2023
$ / shares
|
Apr. 30, 2018
shares
|
|
| Prceedings actions taken by plaintiff description | In the Complaint, the plaintiffs are seeking that the Court issue a declaratory remedy whereby the defendants are required to pay royalties to the plaintiffs at the rate of 7% of the sales and 24% of any and all revenues in consideration for sublicenses related to any product, service or process that contain know-how and technology of Sheba and any and all know-how and technology either developed or supervised by Prof. Ferber in the field of cell therapy, including in the category of the point-of-care platform and any and all services and products in relation to the defendants’ CDMO activity. | ||||||||||||||||||||
| Loss contingency, damages paid, value | ₪ | ₪ 10,000,000 | ||||||||||||||||||||
| Royalty guarantee commitments amount | $ 896,000 | ||||||||||||||||||||
| Plaintiffs request damages amount | ₪ | ₪ 40,143,000,000 | ||||||||||||||||||||
| Warrants exercise price | $ / shares | $ 10.3 | $ 10.3 | $ 10.3 | $ 10.3 | $ 10.3 | $ 10.3 | $ 10.90 | ||||||||||||||
| Issuance of shares | shares | 30,000,000 | 1,186,960 | 1,186,960 | 10,798 | |||||||||||||||||
| Subsequent Event [Member] | |||||||||||||||||||||
| Plaintiffs request damages amount | $ 512,000 | ||||||||||||||||||||
| Common Stock [Member] | |||||||||||||||||||||
| Principal amount of the loan and accrued interest | $ 383,000 | ||||||||||||||||||||
| Unsecured Convertible Note Agreements [Member] | |||||||||||||||||||||
| Unsecured convertible debt | $ 280,000 | ₪ 1,000,000 | |||||||||||||||||||
| Monthly interest rate | 2.00% | 2.00% | |||||||||||||||||||
| Litigation settlement, amount awarded from other party | ₪ | ₪ 427,000 | ||||||||||||||||||||
| Gain loss related to litigation settlement | $ 114,000 | $ 47,000 | |||||||||||||||||||
| Additional amount to be paid for failure litigation settlement amount awarded from other party | ₪ | ₪ 211,000 | ||||||||||||||||||||
| Consultation Agreement [Member] | |||||||||||||||||||||
| Warrants awarded | shares | 80,000 | 80,000 | |||||||||||||||||||
| Warrants exercise price | $ / shares | $ 5.2 | ||||||||||||||||||||
| Unsecured Convertible Note Two Agreements [Member] | |||||||||||||||||||||
| Gain loss related to litigation settlement | $ 57,000 | ||||||||||||||||||||
| Mr Amir Hasidim [Member] | |||||||||||||||||||||
| Unsecured convertible debt | $ 5,000 | ||||||||||||||||||||
| Southern Israel Bridging Fund Two LP [Member] | Mr Amir Hasidim [Member] | |||||||||||||||||||||
| Plaintiffs request damages amount | $ 1,150 | ||||||||||||||||||||
| Litigation settlement interest percentage | 6.00% | ||||||||||||||||||||